Your browser doesn't support javascript.
loading
Pharmacokinetics of flucloxacillin during prolonged intermittent renal replacement therapy in a 76-year-old man.
Fox, Emma; Cheng, Vesa; Rawlins, Matthew; Dyer, John; De Keulenaer, Bart; Page, Michael M; Hoad, Kirsten; Roberts, Jason A.
Afiliación
  • Fox E; Department of Pharmacy, Fiona Stanley Hospital, Perth, WA, Australia.
  • Cheng V; University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
  • Rawlins M; Department of Pharmacy, Fiona Stanley Hospital, Perth, WA, Australia.
  • Dyer J; Department of Infectious Diseases, Fiona Stanley Hospital, Perth, WA, Australia.
  • De Keulenaer B; Department of Intensive Care Medicine, Fiona Stanley Hospital, Perth, WA, Australia.
  • Page MM; School of Surgery, The University of Western Australia, Perth, WA, Australia.
  • Hoad K; Pathwest Laboratory Medicine, Fiona Stanley Hospital, Perth, WA, Australia.
  • Roberts JA; Pathwest Laboratory Medicine, Fiona Stanley Hospital, Perth, WA, Australia.
J Chemother ; 31(7-8): 419-423, 2019.
Article en En | MEDLINE | ID: mdl-31650900
Prolonged intermittent renal replacement therapy (PIRRT) use has been increasing in critically ill patients with kidney dysfunction. PIRRT can affect the pharmacokinetics of many drugs, although no data is available to guide flucloxacillin dosing in this clinical scenario. Herein, we describe the pharmacokinetics of flucloxacillin, given at 1 g every 4 h during PIRRT, in a 76-year-old, critically ill patient with a methicillin-susceptible Staphylococcus aureus (MSSA) prosthetic joint infection complicated by bacteraemia. Blood samples were taken over 2 days including during a 9-h PIRRT session. A two-compartment model was developed to describe differences in clearance of flucloxacillin during PIRRT and off-PIRRT (9.45 vs. 6.89 L/h). A flucloxacillin dose of 1 g every 4 h during PIRRT therapy appeared to attain adequate exposures for MSSA sepsis in this patient, however higher doses may be required for infection sites with poor drug penetration.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Floxacilina / Antibacterianos Tipo de estudio: Prognostic_studies Límite: Aged / Humans / Male Idioma: En Revista: J Chemother Asunto de la revista: ANTINEOPLASICOS / TERAPIA POR MEDICAMENTOS Año: 2019 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Floxacilina / Antibacterianos Tipo de estudio: Prognostic_studies Límite: Aged / Humans / Male Idioma: En Revista: J Chemother Asunto de la revista: ANTINEOPLASICOS / TERAPIA POR MEDICAMENTOS Año: 2019 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Reino Unido